Biotech | January 11, 2022
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The medicine is now approved for eight indications across five different types of cancer in China.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)